Why Insulet’s 20% Collapse Shows That Growth Expectations Had Become Too High
$Insulet(PODD)$ reported strong second-quarter revenue and earnings, yet its shares suffered their largest one-day decline in roughly 17 years. The disconnect shows that investors were focused less on the completed quarter than on signs that US growth for the Omnipod insulin-delivery system is moderating.
Insulet reported on August 5 for the quarter ended June 30. Revenue increased 23.5% to $801.7 million, while adjusted earnings rose 41.5% to $1.66 per share. Total Omnipod revenue increased 24.6% to $795.9 million. US Omnipod revenue grew 20.1% to $544.1 million, while international revenue rose 35.5% to $251.8 million. Insulet’s official second-quarter release provides the results and geographic breakdown.
The bullish thesis rests on recurring consumables and international expansion. Omnipod is a tubeless wearable insulin pump whose disposable Pods generate repeat revenue. Insulet has expanded Omnipod 5 into additional countries, while integration with continuous-glucose monitors can make automated insulin delivery easier to use and widen adoption.
Profitability also improved on an adjusted basis. Adjusted operating income reached $154.5 million, or 19.3% of revenue, up more than 140 basis points from the prior year. That suggests scale can expand profit even as the company invests in launches.
The bearish issue was guidance. Management reduced its constant-currency 2026 total revenue growth forecast to 20%–22%, with most of the change tied to weaker US expectations. Nearly all company revenue comes from Omnipod, so a slowdown in the core product cannot easily be offset elsewhere. Competition, reimbursement changes, manufacturing reliability and the pace of new patient starts remain material risks.
Insulet fell 20.1% to $133.26 on August 5 after trading as low as $126.40. The $126–$133 region is immediate support, while $150 is the first recovery test and $166–$171 is stronger resistance around the pre-results region. The large gap is evidence of an expectations reset, not a reliable forecast of further decline.
The long-term operating evidence leans moderately bullish, but the near-term stock outlook is neutral to moderately bearish until US growth stabilises. The cautious view would be invalidated by accelerating US new-customer additions, higher guidance and continued margin expansion. The longer-term bullish view would fail if competition causes sustained Omnipod share loss or recurring revenue growth drops materially. This is personal opinion for education and is not financial advice.
@Tiger_SG @Tiger_comments @TigerStars @TigerClub @CaptainTiger @Daily_Discussion
Disclaimer: This article is for informational and educational purposes only and does not constitute financial, investment, or trading advice. The views expressed are personal opinions based on publicly available information and are subject to change without notice. Investors should conduct their own research and consider their financial situation, risk tolerance, and investment objectives before making any investment decisions. I do not guarantee the accuracy or completeness of the information presented.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
